Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients

Inclusion Criteria:

• Recurrent or progressive Non-Small Cell Lung Cancer stage IV or IIIB patients.

• Positive EGFR Mutation.

• No previous systemic anticancer therapy.

• Measurable lesion according to RECIST with at least one measurable lesion notpreviously irradiated, unless disease progression has been documented at that site.

• Provision of written informed consent.

Exclusion Criteria:

• Experience of Anti-EGFR(the epidermal growth factor receptor) Monoclonal Antibody orsmall molecular compounds therapy such as gefitinib, erlotinib or Cetuximab.

• Evidence of clinically active Interstitial Lung Diseases (Patients with chronic,stable, radiographic changes who are asymptomatic need not be excluded).

• Known severe hypersensitivity to icotinib or any of the excipients of this product.

• Evidence of any other significant clinical disorder or laboratory finding that makesit undesirable for the subject to participate in the study.